Harrow, Inc. announced three new studies at the ASRS 2026 meeting supporting its retina products IHEEZO, a low-viscosity ocular anesthetic gel, and BYOOVIZ, an FDA-approved biosimilar to LUCENTIS. Early trial data suggest IHEEZO improves patient comfort and safety during eye injections, with further large-scale trial results expected by late 2026. Additionally, real-world data show no increased infection risk with IHEEZO, and Samsung Bioepis shared positive interim findings on BYOOVIZ's post-marketing safety. These findings reinforce Harrow's commitment to evidence-based retina care and long-term product adoption.
The global urology devices market, valued at $39.23 billion in 2025, is projected to grow at a CAGR of 7.35% to reach $80 billion by 2035. Growth is fueled by rising demand for robotic-assisted surgeries, kidney disease management, and minimally inva...
The global quantum photonics market, valued at $0.77 billion in 2025, is projected to grow at a CAGR of 33.79% to reach $14.12 billion by 2035. Growth is fueled by the commercialization of quantum computing, secure quantum communication networks, and...
Patagonia Gold Corp. announced the passing of its former Chairman, Carlos J. Miguens, on July 18, 2026. Miguens played a vital role in the company's growth and was instrumental in advancing its flagship Calcatreu gold and silver project in Argentina....
USA Rare Earth announced that CEO Barbara Humpton will retire on October 1, 2026, with Thras Moraitis, current CEO of Serra Verde Group, succeeding her. Moraitis will become CEO following the completion of the merger between USA Rare Earth and Serra ...
Alternative Ballistics Corporation has partnered with Indonesian company PT Panglima Pandawa Sakti to introduce The Home Defense™, a less-lethal self-defense system, to qualified customers in Indonesia. This marks the company's first international di...
